PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets

Saba Feghhi-Najafabadi, Farhad Riazi-Rad, Mohammad Ali Shokrgozar, Shahriyar Abdoli, Fatemeh Hajari Taheri, Arash Arashkia, Zahra Sharifzadeh

Abstract


Background and purpose: The PD-1/PD-L1 immune checkpoint pathway inhibits T cell function, allowing tumors to escape immune responses. This study aimed to reprogram this inhibitory signaling using a PD-1:CD28 switch receptor (SR) to convert inhibitory signaling into a co-stimulatory signal and to assess its effects on the function of CD4⁺ and CD8⁺ T cells.

Experimental approach: PBMCs isolated from both sources were retrovirally transduced with PD-1:CD28 SR. Intracellular expression of cytokines, including IFN-γ, IL-4, IL-10, as well as the surface CD25 in CD4+ and CD8+ T cells, and the rate of cell apoptosis during engineering and exposure to target cells were assessed.

Findings/Results: Both buffy coat (BC) and whole blood showed comparable transduction efficiency (21.4% versus 18.5%, respectively), but BC yielded nearly double the number of viable PBMCs per 50 mL. Upon stimulation and co-culture with target cells, CD4⁺ SR T cells produced significantly higher levels of IFN-γ, IL-4, and IL-10 compared to CD8⁺ SR T cells. These cytokines also significantly increased in co-culture supernatants exposed to PD-L1⁺ cells. No significant differences were found in CD4/CD8 ratios, CD25 expression, or cytokine profiles between PBMC sources. However, BC-derived T cells showed higher apoptosis rates during co-culture.

Conclusion and implications: BC can be a practical and effective source of PBMCs for T cell engineering. These findings underscore the SR signaling in the activation of CD4+ T cells that may impact the activation of CD8+ T cells, which is essential for effective tumor eradication.

 


Keywords


Blood buffy coat; CD4-positive T-lymphocytes and CD8-positive T-lymphocytes; Immunotherapy; PD-1:CD28 switch receptor; PD-L1; Whole blood.

Full Text:

PDF

References


Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695,1-16. DOI: 10.3389/fphar.2022.868695.

Rahimmanesh I, Khanahmad H. Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer. Res Pharm Sci. 2021;16(5):447-454. DOI: 10.4103/1735-5362.323911.

Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775-790. DOI: 10.1038/s41571-022-00689-z.

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. DOI: 10.1126/science.aar4060.

Nejati M, Soheili M, Salami M, Khedri M. The effect of redox bacteria on the programmed cell death-1 cancer immunotherapy. Res Pharm Sci. 2024;19(2):228-237. DOI: 10.4103/RPS.RPS_28_23.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, Angelis FD, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. DOI: 10.1056/NEJMoa1801005.

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. DOI: 10.1056/NEJMra1703481.

Maali A, Noei A, Feghhi-Najafabadi S, Sharifzadeh Z. A systematic review on the dual role of interleukin-1 in CAR T-cell therapy: enhancer and mitigator. Iran Biomed J. 2024;28(5&6):221-234. DOI: 10.61186/ibj.4444.

Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. 2015;107(8):djv146,1-10. DOI: 10.1093/jnci/djv146.

Velasco Cárdenas RMH, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, et al. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023;24(12):2135-2149. DOI: 10.1038/s41590-023-01658-z.

Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.DOI: 10.1126/science.aaf1292.

Tay JC, Zha S, Wang S. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers. Immunotherapy. 2017;9(16):1339-1349. DOI: 10.2217/imt-2017-0103.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T-Cells in advanced solid tumors. Cancer Res. 2016;76(6):1578-1590. DOI: 10.1158/0008-5472.CAN-15-2524.

Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res. 2021;27(2):473-484. DOI: 10.1158/1078-0432.CCR-20-1457.

Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635-647. DOI: 10.1038/s41577-018-0044-0.

Bove C, Maher J, Glover M. The role of CD4+ CAR T cells in cancer immunotherapy. Transl Cancer Res. 2024;13(5):2580-2586. DOI: 10.21037/tcr-23-2044.

Kravtsov DS, Erbe AK, Sondel PM, Rakhmilevich AL. Roles of CD4+ T cells as mediators of antitumor immunity. Front Immunol. 2022;13:972021,1-9.DOI: 10.3389/fimmu.2022.972021.

Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol. 1999;21(3):339-359. DOI: 10.1007/BF00812261.

Paul MS, Ohashi PS. The roles of CD8+ T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30(9):695-704. DOI: 10.1016/j.tcb.2020.06.003.

Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol. 2004;172(3):1380-1390. DOI: 10.4049/jimmunol.172.3.1380.

Inoue T, Asano Y, Matsuoka S, Furutani-Seiki M, Aizawa S, Nishimura H, et al. Distinction of mouse CD8+ suppressor effector T cell clones from cytotoxic T cell clones by cytokine production and CD45 isoforms. J Immunol. 1993;150(6):2121-2128. PMID: 8450205.

Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1-2): 5-17. DOI: 10.1038/s41417-020-0183-x.

Laux I, Khoshnan A, Tindell C, Bae D, Zhu X, June CH, et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol. 2000;96(3):187-197. DOI: 10.1006/clim.2000.4902.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129. DOI: 10.1126/science.1129003.

Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010;33(8):759-768. DOI: 10.1097/CJI.0b013e3181f1d644.

Rahimmanesh I, Totonchi M, Khanahmad H. The challenging nature of primary T lymphocytes for transfection: effect of protamine sulfate on the transfection efficiency of chemical transfection reagents. Res Pharm Sci. 2020;15(5):437-446. DOI: 10.4103/1735-5362.297846.

Abraham RA, Agrawal PK, Acharya R, Sarna A, Ramesh S, Johnston R, et al. Effect of temperature and time delay in centrifugation on stability of select biomarkers of nutrition and non-communicable diseases in blood samples. Biochem Med (Zagreb). 2019;29(2):020708,1-13.DOI: 10.11613/BM.2019.020708.

Kizhakeyil A, Ong ST, Fazil MHUT, Chalasani MLS, Prasannan P, Verma NK. Isolation of human peripheral blood T-lymphocytes. Methods Mol Biol. 2019;1930:11-17. DOI: 10.1007/978-1-4939-9036-8_2.

Rushdi M, Li K, Yuan Z, Travaglino S, Grakoui A, Zhu C. Mechanotransduction in T cell development, differentiation and function. Cells. 2020;9(2):364,1-22. DOI: 10.3390/cells9020364.

Hashimoto Y, Kinoshita N, Greco TM, Federspiel JD, Jean Beltran PM, Ueno N, et al. Mechanical force induces phosphorylation-mediated signaling that underlies tissue response and robustness in xenopus embryos. Cell Syst. 2019;8(3):226-241.e7. DOI: 10.1016/j.cels.2019.01.006.

Rossy J, Laufer JM, Legler DF. Role of mechanotransduction and tension in T cell function. Front Immunol. 2018;9:2638,1-11. DOI: 10.3389/fimmu.2018.02638.

Harmening DM. Modern blood banking & transfusion practices. 7th ed. Philadelphia: F.A. Davis Company; 2019. pp: 333-354.

Protocol for isolating mononuclear cells from whole blood by density gradient centrifugation. STEMCELL Technologies [Internet]. [cited 2025 June 15]. Available from: https://www.stemcell.com/isolating-mononuclear-cells-from-whole-blood-by-density-gradient-centrifugation.html.

Imai Y, Chiba T, Kondo T, Kanzaki H, Kanayama K, Ao J, et al. Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. Oncol Lett. 2020;20(3):2161-2168. DOI: 10.3892/ol.2020.11757.

Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Neurosci. 2006; Chapter 4: Unit 4.21.DOI: 10.1002/0471142301.ns0421s37.

Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y, et al. Masked chimeric antigen receptor for tumor-specific activation. Mol Ther. 2017;25(1):274-284. DOI: 10.1016/j.ymthe.2016.10.011.

Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol. 2005;174(11):6648-6656. DOI: 10.4049/jimmunol.174.11.6648.

Tran CT, Wolz P, Egensperger R, Kösel S, Imai Y, Bise K, et al. Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Neuropathol Appl Neurobiol. 1998;24(4):293-301. DOI: 10.1046/j.1365-2990.1998.00120.x.

Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973-988. DOI: 10.1016/j.immuni.2016.04.020.

Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005;115(7):1903-1912. DOI: 10.1172/JCI24624.

Li B, Yang C, Jia G, Liu Y, Wang N, Yang F, et al. Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry. BMC Immunol. 2022;23(1):30,1-14.DOI: 10.1186/s12865-022-00505-4.

Repnik U, Knezevic M, Jeras M. Simple and cost-effective isolation of monocytes from buffy coats. J Immunol Methods. 2003;278(1-2):283-292. DOI: 10.1016/S0022-1759(03)00231-X.

Szczepiorkowski ZM, Burnett CA, Dumont LJ, Abhyankar SH. Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion. 2018;58(4):943-950. DOI: 10.1111/trf.14532.

Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med. 2000;192(1):117-122. DOI: 10.1084/jem.192.1.117.

Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med. 2002;196(7):999-1005. DOI: 10.1084/jem.20020666.

Li X, McKinstry KK, Swain SL, Dalton DK. IFN-γ acts directly on activated CD4+ T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals. J Immunol. 2007;179(2):939-949. DOI: 10.4049/jimmunol.179.2.939.

Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep Med. 2023;4(9):101161,1-11. DOI: 10.1016/j.xcrm.2023.101161.

Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368-8377. DOI: 10.1158/0008-5472.CAN-10-1322.

Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3-4):263-272. DOI: 10.1016/j.molimm.2012.03.023.

Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, et al. PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin lymphoma. Front Immunol. 2018;9:1955,1-12. DOI: 10.3389/fimmu.2018.01955.

Rajasekaran K, Xiong V, Fong L, Gorski J, Malarkannan S. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PloS One. 2010;5(9):e12635,1-10. DOI: 10.1371/journal.pone.0012635.

Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55-61. DOI: 10.1016/j.coi.2018.02.004.

Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171. DOI: 10.1038/35093109.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer. 2009;124(7):1594-1604. DOI: 10.1002/ijc.24098.

Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, et al. CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype. J Immunother Cancer. 2023;11(11):e007803,1-14. DOI: 10.1136/jitc-2023-007803.

Ishii K, Pouzolles M, Chien CD, Erwin-Cohen RA, Kohler ME, Qin H, et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 2020;130(10):5425-5443. DOI: 10.1172/JCI130059.

Zhao S, Wang C, Lu P, Lou Y, Liu H, Wang T, et al. Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells. J Immunother Cancer. 2021;9(12):e003176,1-18. DOI: 10.1136/jitc-2021-003176.

Segal BM, Glass DD, Shevach EM. Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol. 2002;168(1):1-4. DOI: 10.4049/jimmunol.168.1.1.

Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693-1704. DOI: 10.1038/s41587-023-02060-8.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.